Open AccessCOVID-19 and thrombosis: Prophylaxis and management
Author(s) -
Kadir Canoğlu,
Bengü Şaylan,
Tayfun Çalışkan
Publication year - 2021
Publication title -
tuberkuloz ve toraks/tüberküloz ve toraks
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.157
H-Index - 18
ISSN - 0494-1373
DOI - 10.5578/tt.20219818
Subject(s) - medicine , covid-19 , asymptomatic , coagulopathy , thrombosis , intensive care medicine , pandemic , low molecular weight heparin , ards , venous thrombosis , disease , infectious disease (medical specialty) , lung
COVID-19 emerged in Wuhan, China in late December 2019, and WHO declared it a pandemic on March 11, 2020. The disease has a wide spectrum ranging from asymptomatic or mild disease to ARDS and death. There have been over 83.9 million cases with 1.8 million deaths worldwide. COVIDassociated coagulopathy appears to be an entity responsible for deaths. Thromboprophylaxis is recommended in patients with COVID-19 to prevent arterial and venous thromboembolism. Low molecular weight heparin such as enoxaparin is often recommended. However, there is still no consensus regarding the treatment dose and duration. The purpose of this review was to observe the pathogenesis of thromboembolic events in COVID-19, current thromboprophylaxis regimens, treatment dosage and duration with guidelines of international scientific institutions.